Antidepressant drugs

Journal of Pain and Symptom Management

Volumn 44, Issue 5, 2012, Pages 763-783

  Howard, Paul ^a   Twycross, Robert ^b   Shuster, John ^c   Mihalyo, Mary ^d   Wilcock, Andrew ^e  

^a Duchess of Kent House   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c VANDERBILT UNIVERSITY   (United States)

^d DUQUESNE UNIVERSITY   (United States)

^e UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; DULOXETINE; FLUOXETINE; IMIPRAMINE; LOFEPRAMINE; MAPROTILINE; METHYLPHENIDATE; MIRTAZAPINE; NEFAZODONE; NORADRENALIN; PAROXETINE; PHENELZINE; PRAMIPEXOLE; REBOXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

AGITATION; AKATHISIA; ANALGESIC ACTIVITY; ANXIETY DISORDER; APPETITE; ATAXIA; ATTENTION; AUTONOMIC DYSFUNCTION; BLADDER SPASM; CHRONIC PAIN; COGNITIVE DEFECT; COGNITIVE THERAPY; CONSTIPATION; DELIRIUM; DEPRESSION; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; EPILEPSY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FIBROMYALGIA; FLU LIKE SYNDROME; GASTROINTESTINAL HEMORRHAGE; GENOTYPE; HEADACHE; HUMAN; HYPERSALIVATION; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; INSOMNIA; LETHARGY; LOW BACK PAIN; MANIA; MIGRAINE; MOOD; MYALGIA; NAUSEA; NERVE CELL PLASTICITY; NEUROPATHIC PAIN; NONHUMAN; ORTHOSTATIC HYPOTENSION; OSTEOARTHRITIS; PAIN; PALLIATIVE THERAPY; PANIC; PARESTHESIA; PARKINSONISM; POSTTRAUMATIC STRESS DISORDER; PRURITUS; QT PROLONGATION; RESTLESSNESS; REVIEW; SEDATION; SEIZURE; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP; STRESS INCONTINENCE; SUICIDAL IDEATION; TENSION HEADACHE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREMOR; UNSPECIFIED SIDE EFFECT; UPREGULATION; VERTIGO; WEIGHT GAIN; XEROSTOMIA;

EID: 84868556226     PISSN: 08853924     EISSN: 18736513     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2012.09.001     Document Type: Short Survey

References (135)

1. E. Castren, and T. Rantamaki Role of brain-derived neurotrophic factor in the aetiology of depression: implications for pharmacological treatment CNS Drugs 24 2010 1 7
2. R.H. Belmaker, and G. Agam Major depressive disorder N Engl J Med 358 2008 55 68
3. P.V. Tran, F.P. Bymaster, R.K. McNamara, and W.Z. Potter Dual monoamine modulation for improved treatment of major depressive disorder J Clin Psychopharmacol 23 2003 78 86
4. E. Akimova, R. Lanzenberger, and S. Kasper The serotonin-1A receptor in anxiety disorders Biol Psychiatry 66 2009 627 635
5. E. Maron, and J. Shlik Serotonin function in panic disorder: important, but why? Neuropsychopharmacology 31 2006 1 11
6. F.T. Nickel, F. Seifert, S. Lanz, and C. Maihöfner Mechanisms of neuropathic pain Eur Neuropsychopharmacol 22 2012 81 91
7. G. McCleane Antidepressants as analgesics CNS Drugs 22 2008 139 156
8. M.M. Heinricher, I. Tavares, J.L. Leith, and B.M. Lumb Descending control of nociception: specificity, recruitment and plasticity Brain Res Rev 60 2009 214 225
9. A. Dogrul, M.H. Ossipov, and F. Porreca Differential mediation of descending pain facilitation and inhibition by spinal 5HT-3 and 5HT-7 receptors Brain Res 1280 2009 52 59
10. C.P. Watson, L. Vernich, M. Chipman, and K. Reed Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial Neurology 51 1998 1166 1171
11. G. McCleane Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study Br J Clin Pharmacol 49 2000 574 579
12. G.J. McCleane Topical doxepin hydrochloride reduces neuropathic pain: a randomised, double-blind, placebo-controlled study Pain Clinic 12 2000 47 50
13. S. Porcelli, C. Fabbri, and A. Serretti Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy Eur Neuropsychopharmacol 22 2012 239 258
14. J. Kirchheiner, and C. Rodriguez-Antona Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders CNS Drugs 23 2009 181 191
15. S.M. Stahl Psychosis and schizophrenia S.M. Stahl, Essential psychopharmacology: Neuroscientific basis and practical applications 3rd ed. 2008 Cambridge University Press New York 247 325
16. National Institute of Mental Health (NIMH). (2006) NIMH's psychoactive drug screening program. Available from http://pdsp.med.unc.edu. Accessed August 2012.
17. S.M. Stahl, J.F. Pradko, and B.R. Haight A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor Prim Care Companion J Clin Psychiatry 6 2004 159 166
18. J.C. Béïque, N. Lavoie, C. de Montigny, and G. Debonnel Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters Eur J Pharmacol 349 1998 129 132
19. M. Hamon, and S. Bourgoin Pharmacological profile of antidepressants: a likely basis for their efficacy and side effects? Eur Neuropsychopharmacol 16 Suppl 5 2006 s625 s632
20. B. Wen, L. Ma, A.D. Rodrigues, and M. Zhu Detection of novel reactive metabolites of trazodone: evidence for CYP2D6-mediated bioactivation of m-chlorophenylpiperazine Drug Metab Dispos 36 2008 841 850
21. J.W. Jefferson, J.F. Pradko, and K.T. Muir Bupropion for major depressive disorder: pharmacokinetic and formulation considerations Clin Ther 27 2005 1685 1695
22. C. Hiemke, and S. Härtter Pharmacokinetics of selective serotonin reuptake inhibitors Pharmacol Ther 85 2000 11 28
23. J.C. Fleishaker Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression Clin Pharmacokinet 39 2000 413 427
24. K. Venkatakrishnan, D.J. Greenblatt, and L.L. von Moltke Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4 J Clin Pharmacol 38 1998 112 121
25. E. Richelson Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs Mayo Clin Proc 72 1997 835 847
26. C.M. Kaye, R.E. Haddock, and P.F. Langley A review of the metabolism and pharmacokinetics of paroxetine in man Acta Psychiatr Scand Suppl 350 1989 60 75
27. P. Schulz, P. Dick, T.F. Blaschke, and L. Hollister Discrepancies between pharmacokinetic studies of amitriptyline Clin Pharmacokinet 10 1985 257 268
28. D.R. Abernethyl, M. Divoll, D.J. Greenblatt, J.S. Harmatz, and R.I. Shader Absolute bioavailability of imipramine: influence of food Psychopharmacology (Berl) 83 1984 104 106
29. K. Linde, M.M. Berner, and L. Kriston St. John's wort for major depression Cochrane Database Syst Rev 4 2008 CD000448
30. National Institute for Health and Clinical Excellence (NICE). Clinical guidleline 90 and 91. Depression. 2009. Available from www.nice.org.uk. Accessed August 2012.
31. S.A. Freeman Suicide risk and psychopharmacology: assessment and management of acute and chronic risk factors J Clin Psychiatry 70 2009 1052 1053
32. G.E. Simon, J. Savarino, B. Operskalski, and P.S. Wang Suicide risk during antidepressant treatment Am J Psychiatry 163 2006 41 47
33. M. Stone, T. Laughren, and M.L. Jones Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration BMJ 339 2009 b2880
34. J.A. Bridge, S. Iyengar, and C.B. Salary Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials JAMA 297 2007 1683 1696
35. C. Martinez, S. Rietbrock, and L. Wise Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study BMJ 330 2005 389
36. D. Gunnell, J. Saperia, and D. Ashby Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review BMJ 330 2005 385
37. D. Fergusson, S. Doucette, and K.C. Glass Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials BMJ 330 2005 396
38. Medicines and Healthcare Products Regulatory Agency. (2007) Antidepressants: suicidal behaviour. Drug Safety Update 2007;1(1): 7-8. Available from http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/ CON079102. Accessed August 21, 2012.
39. R.R. Reeves, and M.E. Ladner Antidepressant-induced suicidality: an update CNS Neurosci Ther 16 2010 227 234
40. C.L. Harden, and M.A. Goldstein Mood disorders in patients with epilepsy: epidemiology and management CNS Drugs 16 2002 291 302
41. J.W. Dailey, and D.K. Naritoku Antidepressants and seizures: clinical anecdotes overshadow neuroscience Biochem Pharmacol 52 1996 1323 1329
42. D. Blumer, G. Montouris, and K. Davies The interictal dysphoric disorder: recognition, pathogenesis, and treatment of the major psychiatric disorder of epilepsy Epilepsy Behav 5 2004 826 840
43. P. Skapinakis, E. Bakola, and G. Salanti Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials BMC Neurol 10 2010 49
44. A. Avila, X. Cardona, and M. Martin-Baranera Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial J Clin Psychopharmacol 23 2003 509 513
45. Zhang LS, Chen ZM, Zhang P. Mirtazapine vs. fluoxetine in treatng Parkinson's disease with depression and anxiety. Medical Journal of Chinese People's Health 2006. DOI: CNKI: SUN:ZMYX.0.2006-2023-2001.
46. A.F. Leentjens, J. Koester, and B. Fruh The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies Clin Ther 31 2009 89 98
47. P. Barone, L. Scarzella, R. Marconi Depression/Parkinson Italian Study Group Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study J Neurol 253 2006 601 607
48. P.K. Gillman Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity Br J Anaesth 95 2005 434 441
49. Baxter K. Stockley's drug interactions (online edition). London: Pharmaceutical Press, 2011. Available from www.medicinescomplete.com. Accessed August 2012.
50. C.M. Kelly, D.N. Juurlink, and T. Gomes Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study BMJ 340 2010 c693
51. Gillman P. Serotonin toxicity, serotonin syndrome: 2006 update, overview and analysis. 2006. Available from www.psychotropical.com. Accessed August 2012.
52. E.J. Dunkley, G.K. Isbister, D. Sibbritt, A.H. Dawson, and I.M. Whyte The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity QJM 96 2003 635 642
53. P.K. Gillman A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action Biol Psychiatry 59 2006 1046 1051
54. I. Whyte Monoamine oxidase inhibitors R.C. Dart, Medical toxicology 2004 Lippincott Williams & Wilkins Baltimore 823 834
55. G.K. Isbister, L.P. Hackett, A.H. Dawson, I.M. Whyte, and A.J. Smith Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity Br J Clin Pharmacol 56 2003 441 450
56. R.J. Flanagan Fatal toxicity of drugs used in psychiatry Hum Psychopharmacol 23 Suppl 1 2008 43 51
57. E.W. Boyer, and M. Shannon The serotonin syndrome N Engl J Med 352 2005 1112 1120
58. P.K. Gillman The serotonin syndrome and its treatment J Psychopharmacol 13 1999 100 109
59. P.K. Gillman Serotonin syndrome: history and risk Fundam Clin Pharmacol 12 1998 482 491
60. I.M. Anderson Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability J Affect Disord 58 2000 19 36
61. C.G. Bhuvaneswar, R.J. Baldessarini, V.L. Harsh, and J.E. Alpert Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review CNS Drugs 23 2009 1003 1021
62. I.M. Anderson, I.N. Ferrier, and R.C. Baldwin Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines J Psychopharmacol 22 2008 343 396
63. S. Jacob, and S.A. Spinler Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults Ann Pharmacother 40 2006 1618 1622
64. S.B. Ross, B. Aperia, and J. Beck-Friis Inhibition of 5-hydroxytryptamine uptake in human platelets by antidepressant agents in vivo Psychopharmacology (Berl) 67 1980 1 7
65. N. Li, N.H. Wallén, M. Ladjevardi, and P. Hjemdahl Effects of serotonin on platelet activation in whole blood Blood Coagul Fibrinolysis 8 1997 517 523
66. C. van Walraven, M.M. Mamdani, P.S. Wells, and J.I. Williams Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study BMJ 323 2001 655 657
67. C. Paton, and I.N. Ferrier SSRIs and gastrointestinal bleeding BMJ 331 2005 529 530
68. Medicines and Healthcare Products Regulatory Agency. Citalopram and escitalopram: QT interval prolongation - new maximum daily dose restrictions (including in elderly patients), contraindications, and warnings. Drug Safety Update 2011;5(5): A1. Available from http://www.mhra.gov.uk/Safetyinformation/ DrugSafetyUpdate/CON137769. Accessed August 21, 2012.
69. U.S. Food and Drug Administration. (2012) Celexa (citalopram hydrobromide) - drug safety communication: Revised recommendations, potential risk of abnormal heart rhythms. 2012. Available from http://www.fda.gov/Safety/ MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm297624.htm. Accessed August 21, 2012.
70. G.K. Isbister, S.J. Bowe, A. Dawson, and I.M. Whyte Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose J Toxicol Clin Toxicol 42 2004 277 285
71. European Medicines Agency. Pharmacovigilance working party March 2010 plenary meeting. 2010. Available from http://www.emea.europa.eu/docs/en-GB/ document-library/Report/2010/04/WC500088721.pdf. Accessed August 2012.
72. Palliativedrugs.com. Survey Jan-Feb 2009. 2009. Available from www.palliativedrugs.com. Accessed August 2012.
73. T. Saarto, and P.J. Wiffen Antidepressants for neuropathic pain Cochrane Database Syst Rev 4 2007 CD005454
74. R.H. Dworkin, A.B. O'Connor, and M. Backonja Pharmacologic management of neuropathic pain: evidence-based recommendations Pain 132 2007 237 251
75. N.B. Finnerup, M. Otto, H.J. McQuay, T.S. Jensen, and S.H. Sindrup Algorithm for neuropathic pain treatment: an evidence based proposal Pain 118 2005 289 305
76. C.P. Watson, I. Gilron, J. Sawynok, and M.E. Lynch Nontricyclic antidepressant analgesics and pain: are serotonin norepinephrine reuptake inhibitors (SNRIs) any better? Pain 152 2011 2206 2210
77. H. Kaur, D. Hota, and A. Bhansali A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial Diabetes Care 34 2011 818 822
78. S.H. Sindrup, F.W. Bach, C. Madsen, L.F. Gram, and T.S. Jensen Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial Neurology 60 2003 1284 1289
79. M. Otto, F.W. Bach, T.S. Jensen, K. Brosen, and S.H. Sindrup Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial Pain 139 2008 275 283
80. S.H. Sindrup, U. Bjerre, and A. Dejgaard The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy Clin Pharmacol Ther 52 1992 547 552
81. M.B. Max, S.A. Lynch, and J. Muir Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy N Engl J Med 326 1992 1287 1288
82. S.H. Sindrup, L.F. Gram, K. Brosen, O. Eshoj, and E.F. Mogensen The selective serotonin re-uptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms Pain 42 1990 135 144
83. C. Christodoulou, A. Douzenis, G. Moussas, and L. Lykouras Effectiveness of mirtazapine in the treatment of postherpetic neuralgia J Pain Symptom Manage 39 2010 e3 e6
84. P. Howard, R. Twycross, and J. Shuster Anti-epileptic drugs J Pain Symptom Manage 42 2011 788 804
85. K. Chandra, N. Shafiq, P. Pandhi, S. Gupta, and S. Malhotra Gabapentin versus nortriptyline in post-herpetic neuralgia patients: a randomized, double-blind clinical trial-the GONIP Trial Int J Clin Pharmacol Ther 44 2006 358 363
86. C.M. Morello, S.G. Leckband, C.P. Stoner, D.F. Moorhouse, and G.A. Sahagian Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain Arch Intern Med 159 1999 1931 1937
87. D. Bansal, A. Bhansali, D. Hota, A. Chakrabarti, and P. Dutta Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial Diabet Med 26 2009 1019 1026
88. I. Gilron, J.M. Bailey, and D. Tu Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial Lancet 374 2009 1252 1261
89. S.N. Raja, J.A. Haythornthwaite, and M. Pappagallo Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial [see comment] Neurology 59 2002 1015 1021
90. J.L. Jackson, W. Shimeall, and L. Sessums Tricyclic antidepressants and headaches: systematic review and meta-analysis BMJ 2010 341 c5222
91. T.O. Staiger, B. Gaster, M.D. Sullivan, and R.A. Deyo Systematic review of antidepressants in the treatment of chronic low back pain Spine 28 2003 2540 2545
92. M.P. Lunn, R.A. Hughes, and P.J. Wiffen Duloxetine for treating painful neuropathy or chronic pain Cochrane Database Syst Rev 4 2009 CD007115
93. A.S. Chappell, M.J. Ossanna, and H. Liu-Seifert Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial Pain 146 2009 253 260
94. L. Rayner, A. Price, and A. Evans Antidepressants for the treatment of depression in palliative care: systematic review and meta-analysis Palliat Med 25 2011 36 51
95. S.D. Block Assessing and managing depression in the terminally ill patient. ACP-ASIM End-of-Life Care Consensus Panel. American College of Physicians - American Society of Internal Medicine Ann Intern Med 132 2000 209 218
96. A. Tylee, and P. Walters Onset of action of antidepressants BMJ 334 2007 911 912
97. M. Candy, L. Jones, R. Williams, A. Tookman, and M. King Psychostimulants for depression Cochrane Database Syst Rev 2 2008 CD006722
98. K. Orr, and D. Taylor Psychostimulants in the treatment of depression: a review of the evidence CNS Drugs 21 2007 239 257
99. L. Rayner, A. Price, M. Hotopf, and I.J. Higginson The development of evidence-based European guidelines on the management of depression in palliative cancer care Eur J Cancer 47 2011 702 712
100. M. Adli, C. Baethge, A. Heinz, N. Langlitz, and M. Bauer Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review Eur Arch Psychiatry Clin Neurosci 255 2005 387 400
101. A.J. Rush, D. Warden, and S.R. Wisniewski STAR*D: revising conventional wisdom CNS Drugs 23 2009 627 647
102. H.G. Ruhé, J. Huyser, J.A. Swinkels, and A.H. Schene Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review J Clin Psychiatry 67 2006 1836 1855
103. G.A. Fava, and L. Mangelli Assessment of subclinical symptoms and psychological well-being in depression Eur Arch Psychiatry Clin Neurosci 251 Suppl 2 2001 II47 II52
104. N. Watanabe, I.M. Omori, and A. Nakagawa Mirtazapine versus other antidepressive agents for depression Cochrane Database Syst Rev 12 2011 CD006528
105. D. Taylor, C. Paton, and R. Kerwin The Maundsley prescribing guidelines 9th ed. 2007 Informa Healthcare London, UK
106. R.C. Shelton, O. Osuntokun, A.N. Heinloth, and S.A. Corya Therapeutic options for treatment-resistant depression CNS Drugs 24 2010 131 161
107. K. Hashimoto Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship Cent Nerv Syst Agents Med Chem 9 2009 197 204
108. N. Rao The clinical pharmacokinetics of escitalopram Clin Pharmacokinet 46 2007 281 290
109. J.L. Carrasco, and C. Sandner Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview Int J Clin Pract 59 2005 1428 1434
110. P.M. Haddad Antidepressant discontinuation syndromes: clinical relevance, prevention and management Drug Safety 24 2001 183 197
111. S.H. Preskorn Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism Clin Pharmacokinet 32 Suppl 1 1997 1 21
112. B. Bandelow, U. Seidler-Brandler, A. Becker, D. Wedekind, and E. Rüther Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders World J Biol Psychiatry 8 2007 175 187
113. D.S. Baldwin, I.M. Anderson, D.J. Nutt British Association for Psychopharmacology Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology J Psychopharmacol 19 2005 567 596
114. National Institute for Health and Clinical Excellence (NICE). Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults: management in primary, secondary and community care. Clinical Guideline 113. 2011. Available from www.nice.org.uk. Accessed August 2012.
115. D. Baldwin, R. Woods, R. Lawson, and D. Taylor Efficacy of drug treatments for generalised anxiety disorder: systemic review and meta-analysis BMJ 342 2011 d1199
116. Y. Okamoto, Y. Matsuoka, and T. Sasaki Trazodone in the treatment of delirium J Clin Psychopharmacol 19 1999 280 282
117. P. Howard, R. Twycross, J. Shuster, M. Mihalyo, and A. Wilcock Antipsychotics J Pain Symptom Manage 41 2011 956 965
118. D.V. Jeste, D. Blazer, and D. Casey ACNP white paper: update on use of antipsychotic drugs in elderly persons with dementia Neuropsychopharmacology 33 2008 957 970
119. K.M. Sink, K.F. Holden, and K. Yaffe Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence JAMA 293 2005 596 608
120. R. Twycross, A. Wilcock, and C.S. Toller Skin care Symptom management in advanced cancer 4th ed. 2009 palliativedrugs.com Nottingham 331 334
121. T.R. Marcy, and M.L. Britton Antidepressant-induced sweating Ann Pharmacother 39 2005 748 752
122. G. Rada, D. Capurro, and T. Pantoja Non-hormonal interventions for hot flashes in women with a history of breast cancer Cochrane Database Syst Rev 9 2010 CD004923
123. S.K. Quella, C.L. Loprinzi, and J. Sloan Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer J Urol 162 1999 98 102
124. J. Weber, M.A. Siddiqui, A.J. Wagstaff, and P.L. McCormack Low-dose doxepin: in the treatment of insomnia CNS Drugs 24 2010 713 720
125. W.B. Mendelson A review of the evidence for the efficacy and safety of trazodone in insomnia J Clin Psychiatry 66 2005 469 476
126. M.J. Mayo, I. Handem, and S. Saldana Sertraline as a first-line treatment for cholestatic pruritus Hepatology 45 2007 666 674
127. Z. Zylicz, M. Krajnik, A.A. Sorge, and M. Costantini Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial J Pain Symptom Manage 26 2003 1105 1112
128. A. Tefferi, and R. Fonseca Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus Blood 99 2002 2627
129. Z. Zylicz, R. Twycross, and E.A. Jones Pruritus in advanced disease 2004 Oxford University Press Oxford, UK
130. R. Twycross, A. Wilcock, and C.S. Toller Urinary symptoms Symptom management in advanced cancer 4th ed. 2009 palliativedrugs.com Nottingham 289 296
131. National Institute for Health and Clinical Excellence (NICE). (2006) Urinary incontinence: the management of urinary incontinence in women. Clinical Guideline 40. 2006. Available from www. http://guidance.nice.org.uk/CG40. Accessed August 2012.
132. R.G. Robinson, R.M. Parikh, J.R. Lipsey, S.E. Starkstein, and T.R. Price Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study Am J Psychiatry 150 1993 286 293
133. H.S. Wortzel, T.J. Oster, C.A. Anderson, and D.B. Arciniegas Pathological laughing and crying: epidemiology, pathophysiology and treatment CNS Drugs 22 2008 531 545
134. R. Twycross, A. Wilcock, and C.S. Toller Alimentary symptoms Symptom management in advanced cancer 4th ed. 2009 palliativedrugs.com Nottingham 61 133
135. M.J. Berber FINISH: remembering the discontinuation syndrome. Flu-like symptoms, Insomnia, Nausea, Imbalance, Sensory disturbances, and Hyperarousal (anxiety/agitation) J Clin Psychiatry 59 1998 255